Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07507643 · ClinicalTrials.gov registry record · Phase 3
A Study of Methylprednisolone in People Having Liver Surgery
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
NCT07507643: Recruiting Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07507643 is a Phase 3 study that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 750 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07507643, a Phase 3 study, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays.
Primary Outcome
To determine whether the administration of preoperative methylprednisolone will result in lower 30-day all-cause morbidity, compared with the standard of care (no methylprednisolone), in participants undergoing elective major hepatectomy for all indications.
Interventions
- DRUG Methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2029-03-27 |
| Phase | Phase 3 |
What NCT07507643 shows while recruiting
NCT07507643 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Methylprednisolone is the first listed.
NCT07507643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07507643 about?
NCT07507643 is a clinical study titled "A Study of Methylprednisolone in People Having Liver Surgery". The purpose of this study is to test whether receiving methylprednisolone before surgery will reduce the side effects of having surgery, such as infections and longer hospital stays.
What is the current status of trial NCT07507643?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2026-03-27. Estimated completion is 2029-03-27.
What interventions are being tested in trial NCT07507643?
The interventions under investigation include: Methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT07507643?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07507643's enrollment target sits among peer trials
750 464th of 2000 higher than 1,529 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI